|  |
| --- |
| **Table S3: On-ECMO data for survivors and non-survivors. All data are median (interquartile range) or counts (percentage) where appropriate** |
| **Variable** | **Survivor(N=2908)** | **Non-survivor(N=1729)** | **p-value** |
| *Hours on ECMO* | 152 (109-222) | 253 (141-389) | 0.00 |
| *Cardiac Complications* |   |   |  |
| Arrhythmia | 81 (3%) | 110 (6%) | 0.00 |
| CPR Required | 28 (1%) | 48 (3%) | 0.00 |
| Inotropes on ECLS | 1170 (38%) | 991 (55%) | 0.00 |
| Myocardial Stun by Echo | 92 (3%) | 90 (5%) | 0.001 |
| Bi-directional PDA | 74 (2%) | 79 (4%) | 0.00 |
| Left to Right PDA | 79 (3%) | 57 (3%) | 0.24 |
| Right to Left PDA | 79 (3%) | 72 (4%) | 0.008 |
| Unknown PDA | 6 (0%) | 13 (1%) | 0.007 |
| Tamponade (air) | 3 (0.1%) | 5 (0.3%) | 0.157 |
| Tamponade (blood) | 17 (1%) | 34 (2%) | 0.000 |
| Tamponade (serous) | 8 (0.3%) | 15 (1%) | 0.008 |
| *Hemorrhagic Complications* |   |   |  |
| Cannula Site Bleeding | 260 (9%) | 215 (12%) | 0.000 |
| DIC | 133 (4%) | 213 (12%) | 0.000 |
| GI | 22 (1%) | 54 (3%) | 0.000 |
| Hemolysis (plfHb>50) | 164 (5%) | 221 (12%) | 0.000 |
| Surgical Site Bleeding | 145 (5%) | 257 (14%) | 0.000 |
| *Infectious Complications* |   |   |  |
| Culture Proven new | 102 (3%) | 179 (10%) | 0.000 |
| WBC < 1500 | 30 (1%) | 41 (2%) | 0.000 |
| *Pulmonary Complications* |   |   |  |
| Pneumothorax | 154 (5%) | 180 (10%) | 0.000 |
| Hemorrhage | 118 (4%) | 202 (11%) | 0.000 |
| *Mechanical Complications* |  |  |  |
| Air in Circuit | 71 (2%) | 81 (4%) | 0.000 |
| Cannula Problems | 241 (8%) | 241 (13%) | 0.000 |
| Clots Bladder | 367 (12%) | 333 (18%) | 0.000 |
| Clots Bridge | 207 (7%) | 175 (10%) | 0.000 |
| Clots Hemofilter | 126 (4%) | 164 (9%) | 0.000 |
| Clots Other | 462 (15%) | 432 (24%) | 0.000 |
| Clots Oxygenator | 411 (13%) | 436 (24%) | 0.000 |
| Cracks Pigtail | 33 (1%) | 31 (2%) | 0.068 |
| Oxygenator Failure | 133 (4%) | 218 (12%) | 0.000 |
| Pump Malfunction | 52 (2%) | 44 (2%) | 0.087 |
| Raceway Rupture | 5 (0.2%) | 13 (1%) | 0.003 |
| *Metabolic Complications*  |   |   |  |
| Glucose<40 | 108 (4%) | 90 (5%) | 0.016 |
| Glucose >240 | 133 (4%) | 118 (7%) | 0.001 |
| Hyperbilirubinemia | 101 (3%) | 116 (6%) | 0.000 |
| pH <7.2 | 79 (3%) | 145 (8%) | 0.000 |
| *Neurologic Complications* |   |   |  |
| Brain Death | 0 (0%) | 36 (2%) | 0.000 |
| CNS Hemorrhage | 235 (8%) | 354 (20%) | 0.000 |
| CNS Infarction | 67 (2%) | 95 (5%) | 0.000 |
| Seizures (Clinical) | 144 (5%) | 160 (9%) | 0.000 |
| Seizures (EEG) | 58 (2%) | 72 (4%) | 0.000 |
| *Renal Complications* |   |   |  |
| CAVHD | 107 (4%) | 131 (7%) | 0.000 |
| Creatinine >3.0 | 12 (0.4%) | 32 (2%) | 0.000 |
| Creatinine 1.5-3.0 | 80 (3%) | 174 (10%) | 0.000 |
| Dialysis | 21 (1%) | 84 (5%) | 0.000 |
| Hemofiltration | 498 (16%) | 615 (34%) | 0.000 |